

Matrix metalloproteinases and cardiovascular diseases

Papazafropoulou A, Tentolouris N

1st Department of Propaedeutic Medicine, Laiko Hospital, Athens University Medical School, Athens, Greece

Abstract

Matrix metalloproteinases (MMPs) are extracellular enzymes that are important in many physiologic and pathologic processes. Their activity is regulated mainly by tissue inhibitors of metalloproteinases (TIMPs). MMPs expression is related with the classical cardiovascular risk factors as well as with inflammation. They play a central role in atherosclerosis, plaque formation, platelet aggregation, acute coronary syndrome, restenosis, aortic aneurysms and peripheral vascular disease. Many studies have shown that commonly prescribed antihypertensive medications, glitazones and statins may influence MMPs activity. The aim of the review is to present literature data on the role of MMPs and their inhibitors in cardiovascular disease. Hippokratia 2009; 13 (2): 76-82

Key words: metalloproteinases, extracellular matrix, atherosclerosis, acute coronary syndromes, aneurysms

Corresponding author: Papazafropoulou A, 1st Department of Propaedeutic Medicine, Laiko Hospital, Athens University Medical School, Athens, Greece, 17 Ag.Thoma street, GR-115 27, Athens, Tel: 0030 210 745 5261, Fax: 210 779 1839, e-mail: pathan@ath.forthnet.gr

Extracellular matrix (ECM) plays a key role for the proper function of the different organs of the human body, including heart and vessels. Changes in the ECM have been implicated in the pathogenesis of several cardiovascular conditions including atherosclerosis, aneurysms, post-angioplasty restenosis and heart failure¹⁻³.

Matrix Metalloproteinases (MMPs) and their inhibitors (Tissue Inhibitors of Metalloproteinases, TIMPs) have a fundamental role in the remodeling of the ECM in both normal and pathological conditions. In addition, MMPs have an important role in cardiovascular diseases, including atherosclerosis⁴, dilated cardiomyopathy⁵ and myocardial repair following infarction⁶.

In the present work we reviewed the existing literature data on the relationship between MMPs and their inhibitors with cardiovascular disease.

MMP structure and function

MMPs were discovered in 1962, in an effort to establish how the metamorphosing tadpole of a frog lost its tail⁷. MMPs are found in a variety of living organisms, from the simplest bacteria up to the human⁸. For example it must be mentioned that metalloproteinase toxin-2 of *Bacteroides fragilis* shares 59% homology in the amino acid sequence with human interstitial MMPs⁸.

MMPs not only take part in biological processes, such as ontogenesis (morphogenesis, angiogenesis, growth), and wound healing^{9,10}, but also during pathological remodeling like tumor growth¹¹. Endothelial cells, smooth muscle cells and fibroblasts can produce MMPs⁴. Oxidative stress, which is involved in cardiovascular disease, can stimulate MMPs production and activation¹². On the

contrary, nitric oxide (NO) inhibits MMPs production by endothelial cells and smooth muscle cells^{13,14}.

MMPs can be divided into 6 groups: collagenases, stromelysins, matrilysins, gelatinases, membrane-type metalloproteinases and zinc- and calcium-dependent endopeptidases⁸. They are usually secreted from the cells as inactive proenzymes⁸. A proenzyme molecule is organized into the 3 basic structural domains: N-terminal propeptide, catalytic domain, and the C-terminal part of the molecule⁸. N-terminal propeptide consists of approximately 80–90 amino acids containing cysteine residue which interacts with catalytic zinc and this ensures the enzymatic latency of the proenzyme⁸.

Regulation of MMPs activity is a complex process including three different levels of activation: a) Regulation of MMPs gene expression¹⁵. Gene expression can be inhibited by some factors like TGF- β , glucocorticoids and retinoic acid¹⁶. Genes for MMPs are expressed only if the tissue is remodelled under either physiological or pathological conditions¹⁷. Gene expression is influenced also by the ECM-cell and cell-cell interactions. As an example, we can mention glycoprotein EMMPRIN (extracellular matrix metalloproteinase inducer) that stimulates MMPs production and was first identified on the surface of human tumor cells¹⁸. b) Regulation of MMPs enzyme activity by cysteine «switch» mechanism¹⁹. The mechanism by which MMPs are activated is mentioned above. However, it must be emphasized that there is a certain reserve of inactive MMPs bound to various components of ECM in the extracellular space. For example, MMP-2 binds to the ECM structures containing elastin, MMP-3 to basal membranes and occasionally to collagen fibrils and MMP-13 to proteoglycans, collagen and elastin¹⁹. c) Inhibition of MMPs by TIMPs. TIMPs are

proteins of size 21–30 kDa. Four homologous molecules termed TIMP-1, -2, -3, -4 have been described²⁰. TIMPs are a family of specific inhibitors of MMPs which are essential for the regulation of normal connective tissue metabolism²¹. TIMP-1 is synthesized by most connective tissue cell types, including mesangial cells and macrophages²¹. TIMP-1 levels are increased in diabetic nephropathy²² and polycystic kidney disease²³. TIMP-2 has only 42% amino acid homology with TIMP-1 but a similar profile of MMP inhibitory activity. Whereas TIMP-1 is highly inducible by cytokines and growth factors, TIMP-2 expression closely matches the pattern of expression of MMP-2²⁴. Expression of TIMP-1 and TIMP-2 is increased significantly in patients with glomerulosclerosis²⁵. TIMP-3 shares only 37% sequence homology with TIMP-1 and is localized mainly to the ECM²⁶. TIMP-4 is the main TIMP in the heart and has an important role in processes such as infarction, heart failure and cardiomyopathy²⁴. Also, TIMPs exert a number of other biological effects in connective tissues, including growth factor activity, inhibition of apoptosis and inhibition of angiogenesis²⁷.

Extracellular matrix and atherosclerosis

It is known that the arterial wall consists of collagen types I and III, macrophages and smooth muscle cells. The evolution of the atherosclerotic plaque from the fatty streak to advanced plaque is associated with an increase in its content of collagen²⁸, in the number of smooth muscle cells²⁹, and in MMP-9 levels⁴. Increased levels of MMP-9 are found more often in patients with unstable angina compared with those with stable angina³⁰. Also, re-stenotic human coronary plaques demonstrate lower MMP-9 expression²⁹. In patients with coronary artery disease higher MMP-9 levels are an independent risk factor of cardiovascular mortality³¹. Increased TIMP-1 levels have been reported consistently in human atherosclerotic plaques, mainly in relation to areas of calcification³². Increased circulating TIMP-1 levels have also been related to stable coronary³³, carotid³⁴ and peripheral artery atherosclerosis³⁴.

Following an acute coronary syndrome, numerous MMPs are expressed and activated in the myocardium, with greater alterations in levels in the ischemic regions and less change in the areas remote from injury³⁶. The same pattern is observed in the peripheral blood over several weeks after an acute coronary syndrome. Elevated levels of TIMP-1 have been reported³⁷, whereas reports of circulating MMP levels during and after acute coronary syndromes have been inconsistent³⁷⁻⁴⁰. In two studies, increased levels of MMPs were observed in the coronary, but not in the peripheral, circulation of patients with acute coronary syndromes^{39,40}. Thrombolytic therapy is a powerful stimulus for MMP expression and collagen degradation⁴¹. In addition, coronary balloon angioplasty results in an immediate release of MMP-9 into the blood⁴².

Extracellular matrix and cardiovascular risk factors

Many studies have shown that all major risk factors for atherosclerotic disease are associated with alterations in circulating levels of various ECM markers^{43,44}.

Age and gender

Older age and male sex have been related to higher plasma TIMP-1⁴³, but not MMP-9⁴⁵. Also, hormone replacement therapy has been demonstrated to reduce plasma MMP-9 levels in postmenopausal women⁴⁶.

Dyslipidemia

Higher blood levels of some MMPs, especially MMP-9, have been observed with increasing total or low density lipoprotein cholesterol (LDL-C) levels^{45,47}. In one study, the plasma TIMP-1 level was related to the total cholesterol/HDL-cholesterol ratio⁵¹. In experimental studies, oxidized LDL has been observed to increase and high density lipoprotein cholesterol (HDL-C) to decrease the production of MMP-1 and MMP-9^{48,49}. In addition, oxidized LDL-C can also decrease TIMP-1 production⁴⁹.

Diabetes mellitus

Increased circulating levels of MMP-9 were observed in patients with diabetes^{45,50}, without any reports for the rest MMPs. However, we showed that plasma levels of MMP-2 and MMP-9 did not differ between diabetic and nondiabetic subjects⁵¹. Only TIMP-1 levels were lower in diabetic subjects compared with nondiabetic subjects⁵¹. The above finding was in accordance with a study showing that TIMP-1 levels are decreased in diabetic subjects⁴⁵.

High glucose concentrations have been demonstrated to induce expression of MMP-1 and MMP-2 from endothelial cells and expression of MMP-9 from macrophages, with no effect on TIMP-1 expression⁵². In one recent study of patients with diabetes, intensified glycaemic and cardiovascular risk management for one year decreased serum cholesterol and glycated hemoglobin levels, and had as a result the decrease of TIMP-1 levels, without any significant change in circulating MMP-9 and TIMP-2⁵³.

Hypertension

Hypertension has been related with increased plasma levels of MMP-9⁴⁵ and TIMP-1⁴³. In addition, increased levels of TIMP-1 in hypertensive persons has been reported in some^{54,55}, but not all⁵⁶, studies. Increased circulating MMP-9 levels have also been observed in subjects with systemic hypertension⁵⁷ or isolated systolic hypertension⁵⁸.

Obesity

Plasma TIMP-1⁴³, but not MMP-9⁴⁵, levels were positively related to body mass index (BMI) in one population-based study. One recent prospective study in obese

women showed that plasma MMP-9 levels decreased one year after gastric banding⁵⁹.

Smoking and alcohol

Large scale studies have shown that smokers had increased plasma levels of MMP-9 and TIMP-1^{43,45}. In smaller studies, smokers have also been found to have higher plasma MMP-9 levels^{60,61}.

An inverse relation between usual alcohol intake and plasma TIMP-1 level was observed in one study⁴⁵. Plasma MMP-9 levels have not been related to alcohol consumption⁴³. Recent alcohol intake does not affect circulating levels of TIMP-1 and MMP-2⁶².

Inflammation

Activation of neutrophils by inflammatory mediators causes release of MMP-8 and MMP-9 from their granules⁶³. Experimental studies suggest that C-reactive protein (CRP) stimulates MMP-1 expression directly, but has no effect on TIMP-1 expression⁶⁴. In small clinical samples, serum CRP levels have been related to circulating levels of MMP-9, but not to those of MMP-2 or MMP-3^{65,66}. Interestingly, infecting macrophages or smooth muscle cells with *Chlamydia pneumoniae* induces MMPs production⁶⁷. Recently, a strong association between the presence of *Chlamydia pneumoniae* antigen and production of MMP-9 in coronary atherosclerotic plaques has been demonstrated⁶⁸.

MMPs and cardiovascular disease

MMPs and atherosclerosis

MMPs influence the process of atherosclerotic lesion formation. One proposed mechanism of the pathogenetic role of MMPs includes the increased migration of vascular smooth muscle cells through the internal elastic lamina into the intimal space, where they proliferate and contribute to plaque formation⁶⁹. In addition, MMPs activity may diminish plaque volume by degrading ECM in the intima⁷⁰. In one study of TIMP-1-deficient mice (in which MMPs activity is increased), a reduced atherosclerotic plaque size was noted⁷¹. Hearts obtained within 24 h post-mortem from patients who died from causes other than coronary artery disease (CAD) showed increased expression of MMP-2 and MMP-9 in plaques of expansively remodeled versus constrictive remodeled segments of atherosclerotic coronary arteries⁷². Finally, one study compared plasma concentrations of MMPs between 53 male patients who had one or more significant stenosis (>50% of diameter) in the coronary arteries with 133 subjects free of cardiovascular disease³³; plasma levels of MMP-9 were significantly higher in the patients with CAD, while plasma concentrations of MMP-2 and MMP-3 were significantly lower in patients with CAD³³.

MMPs and plaque rupture

There is a rapidly expanding body of evidence sug-

gesting that acute coronary syndromes may be influenced by MMPs through degradation of the fibrous cap of vulnerable atherosclerotic lesions⁷³. In one report, specimens from patients with unstable angina showed a 70% increase in intracellular MMP-9, indicating active synthesis, compared to specimens from patients with stable angina³⁰. Similarly, plaques from patients undergoing carotid endarterectomy that were thought to be unstable (patients symptomatic within one month of surgery), showed a more intense stain for MMP-9 than plaques from patients with stable atherosclerotic disease⁷⁴. Also, other studies reported similar findings for the other MMPs^{75,76}.

MMPs and platelet aggregation

The rupture of atheromatous plaques allows dissection of blood into the intima and subsequently the lipid-rich pool⁷⁷. A sequence of events ensues, including platelet aggregation and thrombus formation, which can compromise arterial patency and result in acute coronary syndrome⁷⁷. Some MMPs, like MMP-1 and MMP-2, have been demonstrated to be involved in platelet aggregation^{78,79}. High concentrations of MMP-2 as well as MMP-9 have been shown to inhibit platelet aggregation⁸². Platelets have also been shown to have effects on MMPs secretion⁸². Thus, MMP-9 is synthesized by human monocytes when they are coordinately adherent to collagen and platelets⁸².

MMPs and acute coronary syndromes

Kai et al measured MMP-2 and MMP-9 levels in 50 patients (22 with acute myocardial infarction, 11 with unstable angina, 17 with stable angina and 17 normal volunteers)⁸³. MMP-2 levels were increased by 2-fold in the unstable angina and acute myocardial infarction groups versus the stable angina and controls and were sustained over the 7 day period⁸³.

Another study compared plasma levels of MMP-9 and TIMP-1 in patients with angiographically identified lesions in the left anterior descending artery versus normal subjects³⁹. The study showed that during acute coronary syndromes plasma levels of MMP-9 and TIMP-1 were increased³⁹. Another study evaluated the levels of MMP-1 and MMP-2 in subjects with acute myocardial infarction compared with healthy controls and found that only plasma MMP-2 levels, but not MMP-1, were increased³⁸.

Hirohata et al examined serum concentrations of MMP-1 and TIMP-1 in 13 consecutive patients after their first myocardial infarction who underwent successful reperfusion³⁷. At the end of the study a significant increase of MMP-1 and TIMP-1 was observed, that peaked at 14th day³⁷. Recently, Blankenberg et al reported a strong and independent association between plasma levels of MMP-9 and cardiovascular risk among 1,127 subjects with established CAD³¹. This association was independent of conventional cardiovascular risk factors, but attenuated after adjustment for CRP, IL-6, fibrinogen, and IL-18 levels³¹.

MMPs and post-intervention restenosis of atherosclerotic lesions

Post-intervention restenosis is a common adverse event after endoluminal treatment of atherosclerotic lesions. ECM remodeling by MMPs is involved in each of these processes. For example, balloon injury has been shown to increase MMP-2 and MMP-9 in carotid pig arteries⁸⁴. Similar findings have been found in humans. Hojo et al found increased MMP-2 expression and activity in the coronary circulation following angioplasty and a significant positive correlation between MMP-2 levels post-angioplasty and the degree of angiographic restenosis⁸⁵. Finally, studies using a MMPs inhibitor showed reduction of the intimal hyperplasia and collagen accumulation^{86,87}. In addition, an experimental study showed that the use of doxycycline inhibits MMPs activation in the carotid arteries after angioplasty⁸⁸.

MMPs and aortic aneurysms

Histologic studies of aneurysmal aortas demonstrated specific changes in the extracellular matrix and the aortic wall, including decrease in elastin content and an increase in collagen synthesis⁸⁹. Proteolysis of elastin also results in the release of elastin degradation product, release of MMP-1 and MMP-2, and smooth muscle cell proliferation⁹⁰. Many studies in humans and animals reported increased total MMP-2 levels and MMP-2 activity in aneurysmal aortas compared with normal and atherosclerotic aortas^{91,92}. The presence of MMP-9 in aortic tissue is associated with chronic inflammation⁹³.

Studies both in humans and in animals have shown a relationship between elevated aortic tissue MMP-9 levels and abdominal aortic aneurysms^{94,95}. Petersen et al found that levels of MMP-9 were increased in ruptured aneurysms compared with intact large aneurysms⁹⁶. Furthermore, it has been demonstrated that overexpression of TIMP-1 prevents both elastin depletion and aneurysm formation and rupture in a rat model of abdominal aortic aneurysms⁹⁷.

MMPs and peripheral vascular disease

After occlusion of a major artery, ischemic limbs revascularize via the distinct mechanisms of arteriogenesis and angiogenesis⁹⁸. Many animal and human studies have shown that MMPs, especially MMP-2 and MMP-9, have both been associated with angiogenesis⁹⁹. In an animal model of critical limb ischemia, after 28 days, the limb was revascularized, with perfusion reaching 50% to 80% of the nonischemic control limb⁹⁹. The revascularization was related with the levels of MMP-2 and MMP-9⁹⁹. In the contrary, MMP-9 knockout mice exhibit delayed and incomplete revascularization compared to wild-type mice¹⁰⁰. The existing literature data on human are limited. However, a recent study demonstrated a linear correlation between plasma MMP-9 levels and the severity of ischemia in patients with varying degrees of peripheral arterial occlusive disease³⁵.

Patients with diabetes mellitus and peripheral arterial occlusive disease have a 5-fold increase in the rate of amputation caused by critical limb ischemia than do patients without diabetes¹⁰¹. An experimental model of limb ischemia showed diminished revascularization in diabetic compared to wild type animals, a finding associated with increased expression of MMP-2 and markedly increased expression of MMP-12¹⁰².

MMPs and cardiovascular medications

Several therapies commonly prescribed for patients with cardiovascular diseases may influence MMPs function. Nitroglycerin increases the expression and the activity of MMP-2, MMP-7 and MMP-9, and decreases TIMP-1 levels¹⁰³. Similarly, heparin has been shown to induce MMP-1 and MMP-2 levels¹⁰⁴. On the contrary, recent evidence has shown rosiglitazone decreases levels of MMP-9¹⁰⁵. Calcium channel blockers like amlodipine and diltiazem increase the activity of MMP-1 and MMP-2 in cultured human vascular endothelial cells as well as TIMP-1 levels¹⁰⁶. Decreased MMP-1 activity has been shown with angiotensin II¹⁰⁷. Therefore, angiotensin converting enzyme (ACE) inhibitors may increase the activity of MMP-1¹⁰⁷. Finally, losartan has been shown to increase MMP-2 activity in human vascular smooth cells¹⁰⁸.

Recent observations suggest that statins may exert their beneficial effects on the arterial wall in part by their effects on MMPs and TIMPs. Statins inhibit the secretion of MMPs from rabbit, human smooth muscle cells and macrophages^{109,110} and increase plaque stability¹¹¹. Statins suppress the development of experimental aneurysms in both normal and hypercholesterolemic mice, independently from the lipid-lowering treatment¹¹². Simvastatin reduced serological markers of inflammation and plasma MMP-9 activity¹¹³. In addition, pravastatin decreased lipids, lipid oxidation, inflammation, MMP-2, and cell death and increased TIMP-1 and collagen content in human carotid plaques, confirming its plaque-stabilizing effect in humans¹¹⁴.

Conclusion

In conclusion, MMPs and their inhibitors have a fundamental role in the process of atherosclerosis. MMPs are associated with the classical cardiovascular risk factors and are involved in the different stages of atherosclerosis. Although literature data suggest a role for MMPs activation in cardiovascular diseases, prospective data are needed to evaluate whether interventions aiming at modification of MMPs activity can reduce atherosclerosis. Finally, commonly prescribed medications affect plasma concentrations of MMPs and more research in humans in this field is warranted.

References

1. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. *Physiol Rev* 2005; 85: 1-31

2. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. *Circ Res* 2002; 90: 520–530
3. Shah PK. Inflammation, metalloproteinases, and increased proteolysis— an emerging pathophysiological paradigm in aortic aneurysm. *Circulation* 1997; 96: 2115–2117
4. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. *J Clin Invest* 1994; 94:2493–2503
5. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, non-infarcted and dilated cardiomyopathic human hearts. *Mol Cell Biochem* 1996; 155: 13–21
6. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. *J Mol Cell Cardiol* 1995; 27: 1281–1292
7. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. *Matrix Biol* 2000; 19: 623–629
8. Borkakoti N. Structural studies of matrix metalloproteinases. *J Mol Med.* 2000; 78: 261–268
9. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. *Curr Opin Cell Biol* 1998; 10: 602–608
10. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. *Curr Opin Cell Biol* 1995; 7: 728–735
11. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. *Clin Cancer Res* 2000; 6: 4823–4830
12. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. *J Clin Invest* 1996; 98: 2572–2579
13. Milkiewicz M, Kelland C, Colgan S, Haas TL. Nitric oxide and p38 MAP kinase mediate shear stress-dependent inhibition of MMP-2 production in microvascular endothelial cells. *J Cell Physiol* 2006; 208: 229–237
14. Sinha I, Hannawa KK, Ailawadi G, et al. The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. *Ann Vasc Surg* 2006; 20: 92–98
15. Auble DT, Brinckerhoff CE. The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. *Biochemistry* 1991; 30: 4629–4635
16. Duivenvoorden WC, Hirte HW, Singh G. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. *Clin Exp Metastasis* 1999; 17: 27–34
17. Nagase H. Cell surface activation of progelatinase A (proMMP-2) and cell migration. *Cell Res* 1998; 8: 179–186
18. Lim M, Martinez T, Jablons D, et al. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. *FEBS Lett* 1998; 441: 88–92
19. Lijnen HR, Lupu F, Moons L, Carmeliet P, Gouling D, Collen D. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. *Thromb Haemost* 1999; 81: 799–807
20. Murphy G. Matrix metalloproteinases and their inhibitors. *Acta Orthop Scand Suppl* 1995; 266: 55–60
21. Murphy G, Knauper V, Atkinson S, et al. Cellular mechanisms for focal proteolysis and the regulation of the microenvironment. *Fibrinolysis Proteolysis* 2000; 14: 165–174
22. Wu K, Setty S, Mauer SM, et al. Altered kidney matrix gene expression in early stages of experimental disease. *Acta Anat* 1997; 158: 155–165
23. Schaefer L, Han X, Gretz N, et al. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat. *Kidney Int* 1996; 49: 75–81
24. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. *Circulation Res* 1995; 77: 863–873
25. Carome MA, Striker LJ, Peten EP. Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. *Am J Physiol* 1993; 264: F923–F929
26. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix associated protein with a distinctive pattern of expression in mouse cells. *J Biol Chem* 1994; 269: 9352–9360
27. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. *Eur J Cell Biol* 1997; 74: 111–122
28. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb Vasc Biol* 1995; 15: 1512–1531
29. Brown DL, Hibbs MS, Kearney M, Isner JM. Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. *Am J Cardiol* 1997; 79: 878–882
30. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. *Circulation* 1995; 91: 2125–2131
31. Blankenberg S, Rupprecht HJ, Poirier O, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. *Circulation* 2003; 107: 1579–1585
32. Orbe J, Fernandez L, Rodrguez JA, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. *Atherosclerosis* 2003; 170: 269–276
33. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. *Clin Chem Lab Med* 2001; 39: 380–384
34. Beaudoux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. *Atherosclerosis* 2003; 169: 139–146
35. Tayehjee MH, Tan KT, MacFadyen RJ, Lip GY. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. *J Intern Med* 2005; 257: 110–116
36. Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. *Circulation* 2003; 107: 2857–2863
37. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. *Heart* 1997; 78: 278–284
38. Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. *Jpn Circ J* 2001; 65: 71–75
39. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. *Am Heart J* 2001; 141: 211–217
40. Inoue T, Kato T, Takayanagi K, et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. *Am J Cardiol* 2003; 92: 1461–1464
41. Lee E, Vaughan DE, Parikh SH, et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. *Circ Res* 1996; 78: 44–49
42. Cedro K, Radomski A, Radomski MW, Ruzyllo W, Herbacz

- zynska - Cedro K. Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina: a preliminary study. *Int J Cardiol* 2003; 92: 177–180
43. Sundström J, Evans JC, Benjamin EJ, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. *Eur Heart J* 2004; 25: 1509–1516
 44. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). *Am J Hypertens* 2004; 17: 764–769
 45. Sundström J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures. The Framingham Heart Study. *Circulation* 2004; 109: 2850–2856
 46. Koh KK, Ahn JY, Kang MH, et al. Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women. *Am J Cardiol* 2001; 88: 1423–1426
 47. Kalela A, Pönniö M, Koivu TA, et al. Association of serum sialic acid and MMP-9 with lipids and inflammatory markers. *Eur J Clin Invest* 2000; 30: 99–104
 48. Ardans JA, Economou AP, Martinson JM Jr, Zhou M, Wahl LM. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. *J Leukoc Biol* 2002; 71: 1012–1018
 49. Xu XP, Meisel SR, Ong JM, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. *Circulation* 1999; 99: 993–998
 50. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR γ -activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2003; 23: 283–288
 51. Papazafropoulou A, Perrea D, Moysakis I, Kokkinos A, Katsilambros N, Tentolouris N. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. *J Diabetes Complications*, 2008 [Epub ahead of print]
 52. Death AK, Fisher EJ, McGrath KCY, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. *Atherosclerosis* 2003; 168: 263–269
 53. Tayebjee MH, Lim HS, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes. Effect of 1 year's cardiovascular risk reduction therapy. *Diabetes Care* 2004; 27: 2049–2051
 54. Timms PM, Wright A, Maxwell P, Campbell S, Dawnay AB, Srikanthan V. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. *Am J Hypertens* 2002; 15: 269–272
 55. Laviades C, Varo N, Fernández J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. *Circulation* 1998; 98: 535–540
 56. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. *Int J Cardiol* 2000; 75: 43–47
 57. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: relationship to tissue Doppler indices of diastolic relaxation. *Am J Hypertens* 2004; 17: 770–774
 58. Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. *Arterioscler Thromb Vasc Biol* 2005; 25: 372–378
 59. Laimer M, Kaser S, Kranebitter M, et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. *Int J Obes Relat Metab Disord* 2005; 29: 498–501
 60. Nakamura T, Ebihara I, Shimada N, Koide H. Effect of cigarette smoking on plasma metalloproteinase-9 concentration. *Clin Chim Acta* 1998; 276: 173–177
 61. Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. *Chest* 2003; 124: 1724–1732
 62. Ponomarenko Y, Leo MA, Kroll W, Lieber CS. Effects of alcohol consumption on eight circulating markers of liver fibrosis. *Alcohol Alcohol* 2002; 37: 252–255
 63. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. *Annu Rev Cell Dev Biol* 2001; 17: 463–516
 64. Williams TN, Zhang CX, Game BA, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc γ R2 and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. *Arterioscler Thromb Vasc Biol* 2004; 24: 61–66
 65. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. *J Invest Med* 2003; 51: 295–300
 66. Preston GA, Barrett CV, Alcorta DA, et al. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. *Nephron* 2002; 92: 817–823
 67. Rödel J, Prochnau D, Prager K, Pentcheva E, Hartmann M, Straube E. Increased production of matrix metalloproteinases 1 and 3 by smooth muscle cells upon infection with *Chlamydia pneumoniae*. *FEMS Immunol Med Microbiol* 2003; 38: 159–164
 68. Arno G, Kaski JC, Smith DA, Akiyu JP, Hughes SE, Baboonian C. Matrix metalloproteinase-9 expression is associated with the presence of *Chlamydia pneumoniae* in human coronary atherosclerotic plaques. *Heart* 2005; 91: 521–525
 69. Ravn HB, Falk E. Histopathology of plaque rupture. *Cardiol Clin* 1999; 17: 263–270.
 70. Ardans JA, Blum A, Mangan PR, Wientroub S, Cannon RO 3rd, Wahl LM. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. *Arterioscler Thromb Vasc Biol* 2001; 21: 1265–1268
 71. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. *Circ Res* 2002; 90: 897–903
 72. Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2, and 9 in the human coronary artery. *Atherosclerosis* 2000; 150: 245–253
 73. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8 mediates down regulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. *Circulation* 1999; 99: 420–426
 74. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. *Stroke* 2000; 31: 40–47
 75. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma. A novel collagenolytic pathway suggested by transcriptional profiling. *Circulation* 2001; 104: 1899–1904
 76. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. *Proc Natl Acad Sci USA* 1995; 92: 402–406

77. Davies MJ, Thomas AC. Plaque fissuring—the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. *Br Heart J* 1985; 53: 363–373
78. Galt SW, Lindemann S, Allen L, et al. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. *Circ Res* 2002; 90: 1093–1099
79. Sawicki G, Sanders EJ, Salas E, Wozniak M, Rodrigo J, Radomski MW. Localization and translocation of MMP-2 during aggregation of human platelets. *Thromb Haemost* 1998; 80: 836–839
80. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. *Nature* 1997; 386: 616–619
81. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. *Thromb Haemost* 1999; 82: 1730–1735
82. Galt SW, Lindemann S, Medd D, et al. Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. *Circ Res* 2001; 89: 509–516
83. Kai H, Ikeda H, Yasukawa H, Kai M, et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. *J Am Coll Cardiol* 1998; 32: 368–372
84. Southgate KM, Fisher M, Banning AP, et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. *Circ Res* 1996; 79: 1177–1187
85. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. *Atherosclerosis* 2002; 161: 185–192
86. Li C, Cantor WJ, Nili N, et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. *J Am Coll Cardiol* 2002; 39: 1852–1858
87. Cherr GS, Motew SJ, Travis JA, et al. Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. *Arterioscler Thromb Vasc Biol* 2002; 22: 161–166
88. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. *Am J Pathol* 2002; 160: 1089–1095
89. Carmo M, Colombo L, Bruno A, et al. Alteration of elastin, collagen and their cross-links in abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg* 2002; 23: 543–549
90. Duca L, Floquet N, Alix AJ, Haye B, Debelle L. Elastin as a matrikine. *Crit Rev Oncol Hematol* 2004; 49: 235–244
91. Davis V, Persidskaia R, Baca-Regen L, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol* 1998; 18: 1625–1633
92. Crowther M, Goodall S, Jones JL, Bell PR, Thompson MM. Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. *J Vasc Surg* 2000; 32: 575–583
93. Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. *J Clin Invest* 1995; 96: 318–326
94. Yamashita A, Noma T, Nakazawa A, et al. Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms. *World J Surg* 2001; 25: 259–265
95. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. *J Vasc Interv Radiol* 2000; 11: 1345–1352
96. Petersen E, Gineitis A, Wagberg F, Angquist KA. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. *Eur J Vasc Endovasc Surg* 2000; 20: 457–461
97. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. *J Clin Invest* 1998; 102: 1413–1420
98. Scholz D, Ziegelhoeffer T, Helisch A, et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. *J Mol Cell Cardiol* 2002; 34: 775–787
99. Muhs BE, Plitas G, Delgado Y, et al. Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. *J Surg Res* 2003; 111: 8–15
100. Gagne PJ, Tihonov N, Li X, Glaser J, et al. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. *Am J Pathol* 2005; 167: 1349–1359
101. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *Diabetes Care* 2001; 24: 1433–1437
102. Schiekofer S, Galasso G, Sato K, Kraus BJ, Walch K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. *Arterioscler Thromb Vasc Biol* 2005; 25: 1603–1609
103. Death AK, Nakhla S, McGrath KC, et al. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. *J Am Coll Cardiol* 2002; 39: 1943–1950
104. Tyagi SC, Kumar S, Katwa L. Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. *J Mol Cell Cardiol* 1997; 29: 391–404
105. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation* 2002; 106: 679–684
106. Eickelberg O, Roth M, Mussmann R, et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL-6 and NF-KB in primary human vascular smooth muscle cells. *Circulation* 1999; 99: 2276–2282
107. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. *Adv Exp Med Biol* 1997; 432: 35–44
108. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C, Karakioulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. *J Cardiovasc Pharmacol* 2001; 38: 715–728
109. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and -9 from vascular smooth muscle cells and macrophages. *Arterioscler Thromb Vasc Biol* 2003; 23: 769–775
110. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. *Circulation* 1998; 97: 2433–2444
111. Aikawa M, Rabkin E, Voglic SJ, et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. *Circ Res* 1998; 83: 1015–1026
112. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normaland hypercholesterolemic mice. *Ann Surg* 2005; 241: 92–101
113. Koh KK, Son JW, Ahn JY, et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2002; 22: e19–23
114. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. *Circulation* 2001; 103: 926–933